Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20110
- Development stage
- Phase 2
- Lead developer
- Hansoh BioMedical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HS-20110 is an investigational antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17), developed for the treatment of advanced solid tumors. The drug was independently developed by Shanghai Hansoh Biomedical, a subsidiary of Hansoh Pharmaceutical Group. Its mechanism of action involves targeting CDH17, a protein implicated in tumor growth and progression, delivering cytotoxic agents directly to cancer cells expressing this target. As of early 2025, HS-20110 has received clinical trial approval from the National Medical Products Administration (NMPA) in China and is undergoing Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[1][2][3][5].
- Other names
- HS 20110HS20110HS-20110
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on HS-20110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20110.